Recent News

The latest news from the governments, medical industry and top online sources.

EMA closed 29-30 May | European Medicines Agency (EMA)

The European Medicines Agency (EMA) is closed from 18:00 on Wednesday 28 May 2025 until 08:30 on Monday 2 June 2025. The product emergency hotline is available outside working hours and on public holidays. To reach the emergency hotline, call +31 (0)88 781 7600.  Please note that this number is for emergencies only. Use it […]

Ionis shares phase 3 results for olezarsen in moderate hyper…

The drug was recently approved in the US for familial chylomicronaemia syndrome Ionis Pharmaceuticals has shared positive top-line results from a late-stage study of olezarsen in hypertriglyceridaemia. The phase 3 Essence trial, conducted with Ionis’ research partner the TIMI Study Group, has been evaluating the RNA-targeted drug in adults aged 18 years and older with […]

Leveraging the power of data for public and animal health

The workplan translates the objectives of the European medicines agencies network strategy to 2028 into concrete deliverables. These include strengthening the network’s data analytics capabilities to generate high-quality evidence using both established and novel methods. The clinical study data pilot by EMA’s human medicines committee (CHMP) will continue to clarify the benefits and practicalities of […]

Lynozyfic receives EU approval for relapsed multiple myeloma…

New therapy offers hope for patients with limited option Regeneron Pharmaceuticals has announced that the European Commission has conditionally approved Lynozyfic (linvoseltamab) for adults with relapsed and refractory multiple myeloma. This approval targets patients who have undergone at least three prior treatments and whose disease has progressed. Lynozyfic is a bispecific antibody that activates T […]

EMA business hours over Easter holiday period

EMA’s office is closed from 18:00 on Wednesday 16 April 2025 to 08:30 on Tuesday 22 April 2025. Outside of working hours and on public holidays, it is possible to call the product emergency hotline on +31(0)88 781 7600. Please note that this is an emergency number and should only be used in the event of […]

NHS launches spring COVID-19 booster campaign

An estimated 7.5 million people will be invited to receive the booster The NHS has started delivering its spring COVID-19 vaccine booster to vulnerable individuals across England, with over half a million appointments already booked as of 1 April. Starting from 1 April, eligible groups are being offered an additional dose to increase protection against […]

EMA qualifies first artificial intelligence tool to diagnose…

EMA’s human medicines committee (CHMP) has issued the first Qualification Opinion (QO) on an innovative development methodology based on artificial intelligence (AI). The tool, called AIM-NASH, helps pathologists analyse liver biopsy scans to identify the severity of MASH (metabolic dysfunction associated steatohepatitis; formerly known as non-alcoholic steatohepatitis NASH) in clinical trials. MASH is a condition […]

Orca Bio’s T-cell therapy shows promise in haematological ma…

The company is preparing to submit the results to the FDA this year Orca Bio has shared promising results from a late-stage study of its investigational allogeneic T-cell immunotherapy in patients with haematological malignancies. The phase 3 Precision-T trial has been evaluating the candidate, Orca-T, in patients with acute myeloid leukaemia, acute lymphoblastic leukaemia, high-risk […]

New clinical trial map launched in the EU

A new clinical trial map is now accessible from the public website of the Clinical Trials Information System (CTIS). The map is designed to provide patients and healthcare professionals with easy access to comprehensive, real-time information about clinical trials conducted in their area, increasing access to clinical research in the European Union (EU). Building on […]

Microbiotica unveils new data on MB097 at AACR IO meeting

Data presented in Los Angeles showcases therapy’s potential Microbiotica, a clinical-stage biopharma company, has presented new data on MB097 at the AACR IO meeting held in Los Angeles. MB097 is an oral precision microbiome medicine, currently in development as a co-therapy with KEYTRUDA (pembrolizumab) for advanced melanoma patients. Dr Mat Robinson, Microbiotica’s Senior Vice-President of […]